Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.
Rodriguez CA, Natukunda E, Strehlau R, Venter EL, Rungmaitree S, Cunningham CK, Lalloo U, Kosalaraksa P, HellstrÖm E, Liberty A, McGrath EJ, Kaur M, Leisegang R, Hindman JT, Vieira VA, Kersey K, Cotton MF, Rakhmanina N, Gaur AH.
Rodriguez CA, et al. Among authors: kaur m.
Lancet HIV. 2024 Apr 12:S2352-3018(23)00327-2. doi: 10.1016/S2352-3018(23)00327-2. Online ahead of print.
Lancet HIV. 2024.
PMID: 38621393